Gerhardsson de Verdier Maria, Andersson Maria, Kern David M, Zhou Siting, Tunceli Ozgur
AstraZeneca Research & Development Mölndal, Medical Evidence and Observational Research Centre Mölndal, Sweden.
AstraZeneca Nordic-Baltic, Department of Health Economics, Södertälje, Sweden; AstraZeneca R&D Mölndal, Payer and Real World Evidence, Mölndal, Sweden.
Value Health. 2015 Sep;18(6):759-66. doi: 10.1016/j.jval.2015.04.010. Epub 2015 Jun 22.
Patients with asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have more rapid disease progression and more exacerbations than do those with either condition alone. Little research has been performed, however, in these patients.
The objective was to summarize the health care utilization, costs, and comorbidities of patients with uncontrolled asthma and patients with ACOS.
This retrospective analysis used medical and pharmacy claims from large commercial health plans. The study included patients 6 years or older with a diagnosis of asthma and one or more asthma exacerbation (index event). Patients were classified as having asthma alone or ACOS, and the two groups were matched for age, sex, region, index year, index month, and health plan type. Outcomes included rates of comorbid disease, health care utilization, and costs during the 12 months before and after the index exacerbation.
Among the matched patients with asthma (6,505 ACOS; 26,060 without COPD), mean annual all-cause health care costs were twice as high as for patients with ACOS ($22,393 vs. $11,716; P < 0.0001). Asthma-related costs, representing 29% of total costs, were nearly twice as high among patients with ACOS ($6,319 vs. 3,356; P < 0.0001). Cost differences were driven by large differences in the proportions of patients with an inpatient hospitalization (34.0% vs. 14.6%; P < 0.0001) or emergency department visit (29.6% vs. 19.9%; P < 0.0001). Nearly all prespecified comorbid conditions were more prevalent in the ACOS group.
Patients with asthma and COPD had nearly double the health care costs as did patients with asthma without COPD. The overall disease profile of patients with asthma should be considered when managing patients, rather than treating asthma as a solitary condition.
哮喘与慢性阻塞性肺疾病(COPD)重叠综合征(ACOS)患者比单纯患有这两种疾病之一的患者疾病进展更快,病情加重更频繁。然而,针对这些患者的研究较少。
总结哮喘控制不佳患者和ACOS患者的医疗服务利用情况、费用及合并症。
这项回顾性分析使用了大型商业健康保险计划的医疗和药房理赔数据。研究纳入了6岁及以上诊断为哮喘且有一次或多次哮喘加重(索引事件)的患者。患者被分为单纯哮喘组或ACOS组,两组在年龄、性别、地区、索引年份、索引月份和健康保险计划类型方面进行匹配。结局指标包括索引加重前后12个月内的合并症发生率、医疗服务利用情况和费用。
在匹配的哮喘患者中(6505例ACOS患者;26060例无COPD患者),平均每年全因医疗费用是ACOS患者的两倍(22393美元对11716美元;P<0.0001)。ACOS患者中与哮喘相关的费用占总费用的29%,几乎是无COPD哮喘患者的两倍(6319美元对3356美元;P<0.0001)。费用差异是由住院患者比例(34.0%对14.6%;P<0.0001)或急诊就诊比例(29.6%对19.9%;P<0.0001)的巨大差异驱动的。几乎所有预先设定的合并症在ACOS组中更为普遍。
哮喘合并COPD患者的医疗费用几乎是无COPD哮喘患者的两倍。在管理患者时,应考虑哮喘患者的整体疾病情况,而不是将哮喘作为单一疾病进行治疗。